Arcutis Biotherapeutics Inc (NAS:ARQT)

$ 8.41 0.06 (0.72%) Market Cap: 983.05 Mil Enterprise Value: 821.17 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 36/100

Q2 2024 Arcutis Biotherapeutics Inc Earnings Call Transcript
Aug 14, 2024

$9.58 (-3.72%)

Earnings
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call Transcript
May 14, 2024

$8.13 (+1.75%)

Earnings
Q4 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript
Feb 27, 2024

$10.63 (+9.70%)

Earnings
Arcutis Biotherapeutics Inc ZORYVE (roflumilast) Foam Launch Call Transcript
Jan 22, 2024
Q3 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript
Nov 03, 2023

$2.44 (+9.91%)

Earnings
Arcutis Biotherapeutics Inc Provides Positive Atopic Dermatitis Program Updates Call Transcript
Sep 19, 2023
Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript
Aug 08, 2023

$9.83 (+2.61%)

Earnings
Arcutis Biotherapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript
May 09, 2023

$14.82 (+3.93%)

Earnings
Arcutis Biotherapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Q4 2022 Arcutis Biotherapeutics Inc Earnings Call Transcript
Feb 28, 2023

$16.18 (+1.25%)

Earnings
Arcutis Biotherapeutics Inc Atopic Dermatitis Topline Data Call Transcript
Dec 12, 2022
Q3 2022 Arcutis Biotherapeutics Inc Earnings Call Transcript
Nov 08, 2022

$18.7 (+1.03%)

Earnings
Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Arcutis Biotherapeutics Inc FDA Approval Conference Call Transcript
Aug 01, 2022
Arcutis Biotherapeutics Inc Topline Data Call Transcript
Jun 06, 2022
Arcutis Biotherapeutics Inc Corporate Analyst Meeting Transcript
Mar 28, 2022
Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Arcutis Biotherapeutics Inc DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review - Conference Call Transcript
Feb 01, 2021
Arcutis Biotherapeutics to Discuss Positive Topline Data from Phase 2b Study of ARQ-154 - Conference Call Transcript
Nov 23, 2020
Arcutis Biotherapeutics Inc Announces Positive Topline Data from Phase 2 Seborrheic Dermatitis- Corporate Call Transcript
Sep 29, 2020
Arcutis Biotherapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Arcutis Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020

Arcutis Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 06:10PM GMT

Release Date Price: $25.56 (-10.33%)

Transcript

Graig Suvannavejh

Goldman Sachs - Analyst

Okay. Good afternoon, everyone. Welcome to the 2:10 PM session on day three of the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and US biopharma for Goldman Sachs.

With me today for a fireside chat is Arcutis Biotherapeutics. I'm joined by Frank Watanabe. He's the CEO of the Company. John Smither, the Chief Financial Officer; and Ken Lock, who's the Chief Commercialization Officer. So gentlemen, thank you for joining us. Welcome to your first Goldman Sachs Healthcare Conference. I wish I were out in California with you, with better weather. But the virtual format is going swimmingly well, so I'm glad we're able to do this. So, welcome.

Frank Watanabe

Arcutis Biotherapeutics, Inc. - President and CEO

Our pleasure to be here. Look forward to seeing you guys out in Southern California before too long.

Graig Suvannavejh

Goldman Sachs - Analyst

Great. Thanks so much. Arcutis is a relatively new company, especially as a

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.